



Third Quarter 2022 Results

Delivering on our purpose of using the power of leading-edge science to save and improve lives around the world



Strong business momentum across key growth drivers



Investment and progress in our pipeline



Sustained success scientifically, operationally and commercially



Strong Q3 performance reflects continued business momentum

Updated 2022 financial outlook underscores ongoing success

	Worldwide Sales	GAAP EPS	Non-GAAP EPS ¹
Strong Q3 performance reflects continued business momentum	\$15.0B	\$1.28	\$1.85
Updated 2022 financial outlook underscores ongoing success	\$58.5B	\$5.68	\$7.32
	to \$59.0B	to \$5.73	to \$7.37

Sales

KEYTRUDA[®]
(pembrolizumab) Injection 100 mg

Grew ▲ to
20% **\$5.4B**

GARDASIL[®]
(Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant)

GARDASIL[®].9
(Human Papillomavirus 9-valent Vaccine, Recombinant)

Grew ▲ to
15% **\$2.3B**

Lagevrio²
molnupiravir

\$436M

MSD
Animal Health

Decrease ▼ to
3% **\$1.4B**



“We continue to execute on our strategy, invest in leading-edge science and drive innovation as our colleagues deliver meaningful value for patients - which in turn provides value for our shareholders.

Our third quarter results demonstrate exceptional revenue and underlying earnings growth and sustained performance across our key growth drivers. Inspired by our purpose of saving and improving lives around the world, I am confident we are well-positioned to continue to deliver strong operational performance.”

Rob Davis
Chief Executive Officer and President, MSD

1. A reconciliation of GAAP to non-GAAP EPS can be found in the Company’s earnings release.
2. LAGEVRIO is not approved, but is authorized for emergency use by the FDA.